Jazz Pharmaceuticals Plc Aktie News

New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomes Eight abstracts, including four late-breaking abstracts, underscore Jazz's continued commitment to the epilepsy community and advancing the comprehensive treatment for rare forms of epilepsy For U.S. media and invest...

Jazz Pharmaceuticals PLC (JAZZ) shares up 352% since Big Money bought big in 2015.

Late-breaking HERIZON-GEA-01 presentation highlights the expanding clinical profile of Ziihera across HER2-driven gastrointestinal cancers Jazz to host investor webcast on Friday, January 9, 2026, to review data For U.S. media and investors only DUBLIN , Dec. 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced two abstracts featuring key data for Ziihera ® (zanidatam...

Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

The shortened holiday week is here, and the futures are trading higher this morning.

DUBLIN , Nov. 18, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2025 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 2, 2025, at 6:45 a.m.

Jazz Pharmaceuticals plc surged over 20% after positive Phase 3 data for Ziihera in HER2+ gastroesophageal cancer. JAZZ's diversified portfolio, strong Q3 earnings, and upgraded 2025 revenue guidance support its current double-digit billion valuation. Key risks include upcoming patent expiries, new competition for Xywav, and uncertainty around long-term profitability and revenue replacement.

Jazz Pharmaceuticals plc and Zymeworks Inc. announced positive topline phase 3 results for Ziihera in HER2-positive gastroesophageal adenocarcinoma. Ziihera in combination with chemotherapy and in combination with Tevimbra and chemotherapy outperformed trastuzumab plus chemotherapy, and the triple combination achieved statistically significant overall survival benefit. The GEA indication repres...